PharmAI
PharmAI is a Dresden-based AI drug discovery company offering the DiscoveryEngine platform for 3D protein-structure-based virtual screening and off-target prediction, serving pharmaceutical, biotech, and academic clients through SaaS and project-based services.
- Company typePrivate
- Founded2019
- HeadquartersDresden, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What PharmAI does
PharmAI is a Dresden-headquartered AI-driven drug discovery company that develops and commercializes the DiscoveryEngine platform for structure-based virtual screening and early-stage hit identification. The platform combines interpretable AI, deep learning, and knowledge-based modeling of 3D protein binding-site geometry and non-covalent interaction patterns to explore an 80-billion-dimensional chemical-biological search space and screen against more than 95% of the human proteome. PharmAI reports industry-leading in vitro hit rates of 30% and in vivo hit rates of 16%, alongside a 46% hit rate in a published off-target identification case study with 2bind GmbH.
The company monetizes DiscoveryEngine through a hybrid model: direct SaaS subscriptions for platform access, project-based professional services (Focused Library Service, Scaffold Diversification, Off-Target Identification), and ecosystem assets such as PLIP (an Apache-licensed open-source protein-ligand interaction profiler) and the free Proto web application developed with NanoTemper Technologies. Customers and partners include large pharmaceutical companies, small-to-mid-size biotech firms, academic research groups, and companies such as 2bind, NanoTemper, Chemspace, and Gero.ai, with the company claiming more than 40 completed projects. PharmAI originated from over two decades of structural bioinformatics research at TU Dresden and has been supported by public funding from the German Federal Ministry for Economic Affairs and Energy, the European Social Fund, the European Regional Development Fund, and the state budget of Saxony.
PharmAI firmographics
Firmographics- Name
- PharmAI
- Legal name
- PharmAI GmbH
- Website
- https://pharm.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmAI is a Dresden-based AI drug discovery company offering the DiscoveryEngine platform for 3D protein-structure-based virtual screening and off-target prediction, serving pharmaceutical, biotech, and academic clients through SaaS and project-based services.
- Ownership category
- akta.pro rank
PharmAI industry classification
Industry- Product category
- AI drug discovery software
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where PharmAI is headquartered
LocationHeadquarters
- HQ city
- Dresden
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
PharmAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- DiscoveryEngine SaaS Platform: Software-as-a-Service offering providing AI-powered 3D protein structure analysis platform for drug discovery. Customers can access the technology either indirectly through service projects or directly as SaaS.
- Drug Discovery Service Projects: Project-based services including focused library screening, scaffold diversification, and off-target identification delivered to pharmaceutical and biotech partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
PharmAI product offering
Product offeringCore offering
PharmAI develops and licenses an AI-powered drug discovery platform called DiscoveryEngine that performs 3D protein structure-based virtual screening to identify hit compounds, predict off-target interactions, and diversify chemical scaffolds. The company delivers this technology both as a SaaS subscription and through project-based services for pharmaceutical, biotech, and academic customers.
Product overview
PharmAI offers a unified AI-driven drug discovery platform centered on DiscoveryEngine, which combines 3D protein structure analysis with deep learning for virtual screening. The platform is delivered through service offerings including Focused Library Service (for compound prioritization), Scaffold Diversification (for analogue discovery), and Off-Target Identification Service (for safety profiling). The ecosystem includes PLIP, an open-source protein-ligand interaction profiler, and Proto, a free web application for protein labeling prediction developed with NanoTemper Technologies. All services leverage pre-computed protein structure data and AI algorithms to achieve 30% in vitro hit rates.
Differentiator
Problem solved
Functional benefit
Products and services
- DiscoveryEngine AI-powered platform for 3D protein structure analysis and virtual screening that identifies drug candidates with reported 30% in vitro hit rates, screening against 80-billion-dimensional chemical space and 95% of human proteome. Delivered to pharmaceutical, biotech, and academic customers via SaaS and service engagements.
- Focused Library Service Screening optimization service that reduces large compound libraries (millions) to focused, scaffold-diverse sets of promising candidates based on target binding sites, transforming high-throughput screening into focused screening for pharma and biotech customers.
- Scaffold Diversification Service that diversifies the search space to find analogue compounds with similar binding characteristics, predicting chemical subspaces where interaction probability is highest across millions of compounds.
- Off-Target Identification Service Early-stage de-risking service that predicts potential off-target proteins across 95% of the human proteome and identifies unwanted drug targets that could cause side effects, delivering results in under four weeks.
- PLIP (Protein-Ligand Interaction Profiler) Fully automated open-source command-line tool and web service for characterization of non-covalent interactions between proteins and ligands in 3D structures, expanded to include DNA and RNA interactions and available under Apache License at https://github.com/pharmai/plip.
- Proto Free AI-based web application developed in partnership with NanoTemper Technologies that uses AlphaFold and RCSB PDB protein structures to predict optimal protein labeling strategies for molecular interaction measurements in drug discovery.
Quantifiable outcome
- 30% in vitro hit rate and 16% in vivo hit rate, compared to <0.1% typical HTS rate
- +3 more outcomes
Companies that use PharmAI
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
PharmAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature6 records
PharmAI partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered strategic and core.
- ChemspacestrategicCollaboration to integrate PharmAI's Focused Library Service into Chemspace's world largest online catalog of small molecules and biologics (30+ billion compounds). Enables easier searching for suitable chemical compounds for research projects, reducing the number of substances to be tested in vitro before purchase.
- Telekom TechBoostcorePharmAI joined Telekom TechBoost Grow program gaining access to computing power, scalability, and professional cloud support via Open Telekom Cloud (up to €100,000 credit). Program provides hosting infrastructure for SaaS platform at high data security and privacy standards.
- NanoTemper TechnologiescorePartnership to develop biophysical tools combining PharmAI's DiscoveryEngine AI software with NanoTemper's optical measurement instruments for molecular interaction analysis. Joint launch of Proto, a free AI-based web application for protein labeling prediction using AlphaFold and RCSB Protein Data Bank structures. One of the first commercial applications using AlphaFold database.
- 2bind GmbHcoreStrategic partnership for in vitro validation of AI-predicted hit compounds using biophysical platforms including MicroScale Thermophoresis (MST). 2bind provides validation of DiscoveryEngine predictions and compound handling services, perfectly complementing PharmAI's in silico capabilities. Joint projects achieved up to 46% hit rates in off-target identification.
- PharmAI Discovery GmbHcorePharmAI Discovery GmbH is the parent company. In March 2024, PharmAI GmbH became a 100% subsidiary of PharmAI Discovery GmbH, unifying teams, intellectual property, and strategic focus under one structure.
- Technische Universität Dresden (TU Dresden)corePharmAI was founded in 2019 as a spin-off from TU Dresden. The company traces its roots to early 2000s research at TU Dresden where foundational work in structural bioinformatics and computational drug discovery was conducted. In September 2025, PharmAI is developing hybrid quantum-classical methods combining AI-driven discovery with TU Dresden's quantum expertise.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
PharmAI competitors and assessment
Company assessmentDirect peers
- Atomwise: AI-driven small molecule drug discovery company using structure-based virtual screening. Directly comparable to PharmAI's DiscoveryEngine in target space, customer profile (pharma/biotech) and delivery model.
- XtalPi: AI + quantum physics-powered drug discovery platform serving global pharma with virtual screening, de novo design and prediction services. Highly comparable technology stack and enterprise SaaS-plus-services model.
- Iambic: AI-driven drug discovery company combining foundation models with physics-based simulation for small molecule design. Comparable in stage, AI-led discovery approach and pharma partnership model to PharmAI.
- Schrödinger: Public computational chemistry platform providing physics-based and AI-enabled molecular design and virtual screening to pharma. Closely aligned with PharmAI's structure-based approach and pharma enterprise customer base, though at much larger scale.
Broad incumbents
- Exscientia: AI-driven precision medicine company with end-to-end discovery capabilities and pharma partnerships. Larger and broader in scope than PharmAI but operates in the same AI drug discovery category.
- InSilico Medicine: AI-driven end-to-end drug discovery company with platforms covering target identification, generative chemistry and clinical development. Competes with PharmAI for enterprise pharma discovery deals at a larger scale.
- Insitro: Well-capitalized AI-driven drug discovery company combining ML with high-throughput biology. Targets similar pharma partners but operates a much broader platform spanning target ID through IND-enabling work.
- BenevolentAI: AI-driven drug discovery company focused on target identification and drug repositioning across multiple therapeutic areas. Comparable in target customer profile (large pharma) but broader in therapeutic and platform scope.
- Recursion: Public AI-driven drug discovery company combining high-throughput biology with machine learning. Operates at much larger scale than PharmAI and competes for the same large-pharma discovery partnerships.
Emerging players
- Lantern Pharma: AI-driven oncology drug development company using its RADR platform to identify and develop therapeutic candidates. Comparable in stage and AI-led approach but narrower in therapeutic focus (oncology) and platform scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
PharmAI social profiles
Digital presencePharmAI compliance and trust
Trust signalCompliance1 record
PharmAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmAI leadership team
Management profileNumber of profiles
Profiles12 records
PharmAI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmAI
What does PharmAI do?
PharmAI develops and licenses an AI-powered drug discovery platform called DiscoveryEngine that performs 3D protein structure-based virtual screening to identify hit compounds, predict off-target interactions, and diversify chemical scaffolds. The company delivers this technology both as a SaaS subscription and through project-based services for pharmaceutical, biotech, and academic customers.
Is PharmAI a public or private company?
PharmAI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PharmAI founded?
PharmAI was founded in 2019. It employs 11 to 50 people.
Where is PharmAI based?
PharmAI is headquartered in Dresden, Germany, in the Europe region.
How does PharmAI make money?
Two revenue lines are on record. DiscoveryEngine SaaS Platform is the primary driver. The others are drug Discovery Service Projects.
Who are PharmAI's main competitors?
Direct peers on record are Atomwise, XtalPi, Iambic and Schrödinger. Broad incumbents are Exscientia, InSilico Medicine, Insitro, BenevolentAI and Recursion. Lantern Pharma is listed as an emerging player.
Does PharmAI have an API?
No public API is recorded for PharmAI.
What industry is PharmAI in?
PharmAI's product category is AI drug discovery software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery).